Adjuvant radiation therapy for patients with type II endometrial carcinoma: Impact on tumor recurrence and survival

International Journal of Gynecological Cancer

Volumn 23, Issue 4, 2013, Pages 763-768

  Yechieli, Raphael ^a   Rasool, Nabila ^a   Robbins, Jared R ^a   Cogan, Chad M ^a   Elshaikh, Mohamed A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Chemotherapy; Clear cell; Endometrial carcinoma; Radiation treatment; Type II; Uterine serous

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; IRIDIUM 192; PACLITAXEL; PLATINUM DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; DISEASE SPECIFIC SURVIVAL; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH VESSEL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOTHERAPY EQUIPMENT; RECURRENCE FREE SURVIVAL; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84879943259     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828b15cb     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642-646.
3. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002;54:79-85.
4. Sakuragi N, Hareyama H, Todo Y, et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand. 2000;79:311-316.
5. FaderAN, Drake RD, O'MalleyDM, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119-2127.
6. Smith MR, PetersWA 3rd, Drescher CW. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol. 1994;170:1677-1681 discussion 81-82.
7. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
8. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for stage I endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834-838.
9. Murphy KT, Rotmensch J, Yamada SD, et al. Outcome and patterns of failure in patients with stages I-IV clear cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1272-1276.
10. Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108:293-297.
11. Robbins JR, Siddiqui MS, Al-Wahab Z, et al. Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma. Eur J Gynecol Oncol. 2012;5:449-454.
12. Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the breast and female genital organs. In: Tavassoli FA, Devilee P, eds. WHO Pathology and Genetics. Lyon, France: IARC Press; 2003:221-232.
13. Kim A, Schreiber D, Rineer J, et al. Impact of adjuvant external-beam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e639-e644.
14. Hamilton CA, Liou WS, Osann K, et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2005;63:839-844.
15. Batchelor EC, Watkins JM, Creasman WT, et al. The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma. Eur J Obstet Gynecol Reprod Biol. 2008;141:163-168.
16. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95:593-596.
17. Barney BM, Petersen IA, Mariani A, et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys. 2013;127:109-115.
18. Kiess AP, Damast S, Makker V, et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol. 2012;127:321-325.
19. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100:349-354.
20. Vance S, Yechieli R, Cogan C, et al. The prognostic significance of age in surgically staged patients with type II endometrial carcinoma. Gynecol Oncol. 2012;126:16-19.
21. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - results from two randomized studies. Eur J Cancer. 2010;46:2422-2431. E-pub 2010 Jul 7.
22. Geller MA, Ivy J, Dusenbery KE, et al. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. Gynecol Oncol. 2010;118:19-23.
23. Kelly MG, O'Malley D, Hui P, et al. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol. 2004;95:469-473.
24. Boruta DM 2nd, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153. E-pub 2009.
25. Martinez AA, Weiner S, Podratz K, et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol Oncol. 2003;90:537-546.